stockrow
Saturday 7 November 2026
Export XRTX’s income statement to Excel — free account
XORTX Therapeutics Inc.
XRTX Healthcare Biotechnology
- EPS
- −10.5%
- Free cash flow
- −318.4%
Quarter to June 2026, against a year earlier
0.90
0.02
−2.17%
Follow XRTX
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | — | — | 3 | 16 | — | +392.3% | |
| Gross margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — | 0.00 | 0.0 pt | ||||||
| EBT | — | — | (3) | 0 | (1) | (1) | (8) | (2) | (3) | (3) | (4) | (0.6%) | ||||||
| EBT margin, % | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | — | 0 | (3) | 0 | (1) | (1) | (8) | (2) | (3) | (3) | (4) | n/m | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | — | — | (4.74) | (0.82) | (6.48) | (6.30) | (24.75) | (5.45) | (5.75) | (2.80) | (2.73) | (7.3%) | ||||||
| Cash flow | — | — | (1.16) | (0.23) | (3.67) | (22.11) | (30.28) | (16.61) | (6.39) | (2.92) | (3.15) | +14.1% | ||||||
| Capex | — | — | 0.00 | 0.00 | (0.07) | (0.15) | (0.15) | (0.12) | (0.07) | (0.06) | (0.11) | n/m | ||||||
| Free cash flow | — | — | (1.16) | (0.23) | (3.74) | (22.25) | (30.44) | (16.72) | (6.46) | (2.98) | (3.26) | +14.4% | ||||||
| Book value | — | — | 0.40 | (0.27) | 6.33 | 61.04 | 23.64 | 11.71 | 5.79 | 2.20 | 3.40 | +27.4% | ||||||
| Shares, m | — | — | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | +7.1% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | 0 | — | |||||
| P/S | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| P/B | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | 0 | — | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | — | — | (1) | 0 | (1) | (5) | (9) | (7) | (4) | (3) | (5) | +22.2% | |||||
| Capex | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | +9.0% | ||||||
| Free cash flow | — | — | (1) | 0 | (1) | (5) | (9) | (7) | (4) | (3) | (5) | +22.6% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | — | — | 0 | 0 | 1 | 16 | 9 | 3 | 2 | 1 | 2 | +41.5% | |||||
| Net debt | — | — | (1) | (1) | 0 | (15) | (10) | (3) | (2) | (1) | (1) | +3.8% | ||||||
| Shareholders’ equity | — | — | 0 | 0 | 1 | 13 | 7 | 5 | 3 | 2 | 6 | +36.5% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | — | — | (596.89) | (54.81) | (75.31) | (13.67) | (51.53) | (24.19) | (69.30) | (78.38) | (83.78) | +518.5 pt | |||||
| ROIC | — | — | 0.00 | 0.00 | (80.42) | 0.00 | 0.00 | (316.40) | (298.29) | (166.80) | (54.27) | (166.8) pt | ||||||
| ROE | — | — | (7,549.59) | (1,316.93) | (247.50) | (18.45) | (75.86) | (37.08) | (83.06) | (98.00) | (99.24) | +7,451.6 pt | ||||||
| People | ||||||||||||||||||
| People | Employees | — | — | — | — | 1 | 2 | 3 | 17 | 17 | 15 | — | +71.9% | |||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
XORTX Therapeutics Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GNPX GENPREX | $1.7M | — (loss-making) | — | — | n/m | −32.98% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PPCB Propanc Biopharma Inc | $1.7M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | Compare |
| XRTX XORTX Therapeutics Inc. | $1.7M | — (loss-making) | — | — | n/m | −318.40% (below 0%: shrinking) | 0.00% | 0.00% | |
| GOVX GeoVax Labs Inc. | $1.6M | — (loss-making) | — (loss-making) | +183.44% (above 0%: growing) | n/m | +15.81% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ITRMF Iterum Therapeutics PLC | $1.6M | — (loss-making) | — (loss-making) | +110.81% (above 0%: growing) | n/m | −179.15% (below 0%: shrinking) | 94.87% | (1,982.31%) | Compare |
| OGEN Oragenics, Inc. | $1.6M | — (loss-making) | — (loss-making) | −75.33% (below 0%: shrinking) | n/m | −66.37% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| VRAX Virax Biolabs Group Limited | $1.6M | — (loss-making) | — (loss-making) | — | −855.56% (below 0%: shrinking) | +32.24% (above 0%: growing) | (53.57%) | 0.00% | Compare |
| KAPA Kairos Pharma, Ltd. | $1.5M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | — (loss-making) | — (loss-making) | +392.01% (above 0%: growing) | n/m | +114.65% (above 0%: growing) | 100.00% | 96.83% | Compare |
| Median of peers | $1.6M | — | — | +147.13% | — | −29.34% | 97.44% | 0.00% |